Several other hedge funds also recently modified their holdings of the stock. IFM Investors Pty Ltd acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth $704,000. Teachers Retirement System of The State of Kentucky raised its stake in Thermo Fisher Scientific by 7.1% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 89,740 shares of the medical research company’s stock worth $12,662,000 after buying an additional 5,915 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth $107,251,000. Empire Life Investments Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $3,159,000. Finally, Barings LLC raised its stake in Thermo Fisher Scientific by 58.6% in the fourth quarter. Barings LLC now owns 14,369 shares of the medical research company’s stock valued at $2,027,000 after buying an additional 5,310 shares during the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.
Sharkey Howes & Javer boosted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 733 shares of the medical research company’s stock after buying an additional 7 shares during the period. Sharkey Howes & Javer’s holdings in Thermo Fisher Scientific were worth $113,000 at the end of the most recent reporting period.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded up 0.55% during trading on Wednesday, hitting $176.44. The stock had a trading volume of 1,370,096 shares. The firm has a market cap of $68.81 billion, a price-to-earnings ratio of 30.74 and a beta of 1.06. The stock has a 50-day moving average of $176.88 and a 200 day moving average of $164.14. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 earnings per share. On average, analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio is 10.45%.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a report on Tuesday. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday. Deutsche Bank AG set a $200.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Saturday, June 10th. Barclays PLC reiterated an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $188.56.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel P. Shine sold 4,688 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the transaction, the insider now directly owns 29,200 shares in the company, valued at $5,018,896. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock worth $4,702,223 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.